Linearity [Regulatives / Guidelines]

posted by jag009  – NJ, 2022-01-24 16:06 (761 d 23:09 ago) – Posting: # 22752
Views: 2,051

Hi Ohlbe,

❝ Does your drug show linear PK ? If not: does it show more-than-proportional increase (then the highest strength would be more sensitive to show differences in BA) or less-than-proportional increase (lowest strength would be more sensitive, giving you good arguments) ?

Yes its linear PK. I read the FDA guidance about Guidance, for NDA it seeems "possible" as long as one can provide safety and efficacy data.


Complete thread:

UA Flag
 Admin contact
22,911 posts in 4,806 threads, 1,635 registered users;
39 visitors (0 registered, 39 guests [including 2 identified bots]).
Forum time: 15:15 CET (Europe/Vienna)

The history of statistics is like a telephone directory:
the plot is boring, full of numbers and the cast is endless.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz